Gene expression profile at the single-cell level of skin and PBMC samples collected from patients with severe cutaneous adverse drug reactions (SCADR).

Single-cell RNA sequencing (scRNA-seq) provides an opportunity to decipher potential cell-cell interactions and cell-type specific transcriptomic changes, amenable to therapeutic intervention, particularly in rare diseases with heterogenous clinical presentations and lacking experimental animal models, such as SCADR.

We performed scRNA-seq on the skin of four patients diagnosed with SCADR syndromes including one toxic epidermal necrolysis (TEN), one Stevens-Johnson syndrome (SJS), one acute generalized exanthematous pustulosis (AGEP), and one extensive drug-related maculopapular rash (MPR), and three healthy controls.